IVICENTAMAB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 05:03:06 GMT 2025` Edited by `admin` on `Wed Apr 02 05:03:06 GMT 2025`
Protein Type	BISPECIFIC ANTIBODY
Protein Sub Type	IGG1\|KAPPA
Sequence Origin	HUMANIZED RABBIT
Sequence Type	COMPLETE
Record UNII	4O7JS64H45
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IVICENTAMAB

Official Name

English

DuoHexaBody-CD37

Preferred Name

English

ivicentamab [INN]

Common Name

English

IMMUNOGLOBULIN G1 (408-LEUCINE,433-GLYCINE,DE-450-LYSINE), ANTI-(HUMAN CD37 ANTIGEN) (HUMAN-ORYCTOLAGUS CUNICULUS BIPARATOPIC MONOCLONAL 3009-016-H5L2 .GAMMA.1-CHAIN), DISULFIDE WITH (90-SERINE) HUMAN-ORYCTOLAGUS CUNICULUS BIPARATOPIC MONOCLONAL 3009-016

Common Name

English

GEN 3009 [WHO-DD]

Common Name

English

Code System Code Type Description

CAS

2364496-42-2

Created by admin on Wed Apr 02 05:03:06 GMT 2025 , Edited by admin on Wed Apr 02 05:03:06 GMT 2025

PRIMARY

NCI_THESAURUS

C172443

Created by admin on Wed Apr 02 05:03:06 GMT 2025 , Edited by admin on Wed Apr 02 05:03:06 GMT 2025

PRIMARY

SMS_ID

300000011321

Created by admin on Wed Apr 02 05:03:06 GMT 2025 , Edited by admin on Wed Apr 02 05:03:06 GMT 2025

PRIMARY

FDA UNII

4O7JS64H45

Created by admin on Wed Apr 02 05:03:06 GMT 2025 , Edited by admin on Wed Apr 02 05:03:06 GMT 2025

PRIMARY

INN

11702

Created by admin on Wed Apr 02 05:03:06 GMT 2025 , Edited by admin on Wed Apr 02 05:03:06 GMT 2025

PRIMARY

From	To
1_22	1_95
1_147	1_203
1_264	1_324
1_370	1_428
1_223	3_217
1_229	2_228
1_232	2_231
2_22	2_95
2_146	2_202
2_263	2_323
2_369	2_427
3_23	3_88
3_137	3_197
4_22	4_87
4_136	4_196
2_222	4_216

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_300
N	2_299

Related Record Type Details


					VTD13G7FDK

LEUKOCYTE ANTIGEN CD37

TARGET->LIGAND

Comments:

A bispecific CD37 antibody with the E430G hexamerization-enhancing mutation targeting two non-overlapping epitopes on CD37 (biparatopic), demonstrated potent and superior CDC activity compared to other CD37 antibody variants

Amount:

Related Record Type Details


					4O7JS64H45

ACTIVE MOIETY

Comments:

Potential therapy for B-cell malignancies

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL